1
|
Song C, Wang K, Qian B, Lu J, Qiao M, Qiu Y, Wang B, Yu Y. Nrf-2/ROS/NF-κB pathway is modulated by cynarin in human mesenchymal stem cells in vitro from ankylosing spondylitis. Clin Transl Sci 2024; 17:e13748. [PMID: 38450992 PMCID: PMC10918724 DOI: 10.1111/cts.13748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 01/21/2024] [Accepted: 02/06/2024] [Indexed: 03/08/2024] Open
Abstract
Ankylosing spondylitis (AS) is an immune chronic inflammatory disease, resulting in back pain, stiffness, and thoracolumbar kyphotic deformity. Based on the reported anti-inflammatory and antioxidant capacities of cynarin (Cyn), this study explored its protective role and molecular mechanisms in mesenchymal stem cells (MSCs) from AS. The target pathways and genes were verified using Western blotting, quantitative real-time polymerase chain reaction, and immunofluorescent staining, while molecular docking analysis was conducted. In AS-MSCs, we found that the expression levels of p-NF-κB, IL-6, IL-1β, and TNF-α were higher and IκB-α, Nrf-2, and HO-1 were lower compared with healthy control (HC)-MSCs. With molecular docking analysis, the biding affinities between Cyn and Keap1-Nrf-2 and p65-IκB-α were predicted. The mRNA and protein expression of p-NF-κB, IL-6, IL-1β, and TNF-α and the reactive oxygen species (ROS) generation were downregulated following Cyn administration. Meanwhile, the expression level of IκB-α, Nrf-2, and HO-1 were significantly increased after Cyn pretreatment. The results suggested that the protective mechanisms of Cyn in AS-MSCs were based on enhancing the antioxidation and suppression of excessive inflammatory responses via Nrf-2/ROS/NF-κB axis. Our findings demonstrate that Cyn is a potential candidate for alleviating inflammation in AS.
Collapse
Affiliation(s)
- Chenyu Song
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Kaiyang Wang
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Bangping Qian
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Jingshun Lu
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Mu Qiao
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Yong Qiu
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Bin Wang
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| | - Yang Yu
- Division of Spine Surgery, Department of Orthopedic SurgeryNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjingChina
| |
Collapse
|
2
|
Joshi JM, Muttigi MS, Upadhya R, Seetharam RN. An overview of the current advances in the treatment of inflammatory diseases using mesenchymal stromal cell secretome. Immunopharmacol Immunotoxicol 2023:1-11. [PMID: 36786742 DOI: 10.1080/08923973.2023.2180388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The growing interest in mesenchymal stromal cell (MSC) therapy has been leading to the utilization of its therapeutic properties in a variety of inflammatory diseases. The clinical translation of the related research from bench to bedside is cumbersome due to some obvious limitations of cell therapy. It is evident from the literature that the MSC secretome components mediate their wide range of functions. Cell-free therapy using MSC secretome is being considered as an emerging and promising area of biotherapeutics. The secretome mainly consists of bioactive factors, free nucleic acids, and extracellular vesicles. Constituents of the secretome are greatly influenced by the cell's microenvironment. The broad array of immunomodulatory properties of MSCs are now being employed to target inflammatory diseases. This review focuses on the emerging MSC secretome therapies for various inflammatory diseases. The mechanism of action of the various anti-inflammatory factors is discussed. The potential of MSC secretome as a viable anti-inflammatory therapy is deliberated.
Collapse
Affiliation(s)
- Jahnavy Madhukar Joshi
- Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Manjunatha S Muttigi
- Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Raghavendra Upadhya
- Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Raviraja N Seetharam
- Manipal Center for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, Karnataka, India
| |
Collapse
|
3
|
Skrzypkowska M, Stasiak M, Sakowska J, Chmiel J, Maciejewska A, Buciński A, Słomiński B, Trzonkowski P, Łuczkiewicz P. Cytokines and chemokines multiplex analysis in patients with low disease activity rheumatoid arthritis. Rheumatol Int 2022; 42:609-619. [PMID: 35179632 PMCID: PMC8940835 DOI: 10.1007/s00296-022-05103-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Accepted: 02/03/2022] [Indexed: 12/20/2022]
Abstract
Rheumatoid arthritis is a severe chronic autoimmune disorder that results from pathological activation of immune cells and altered cytokine/chemokine network. The aim of our study was to evaluate concentrations of chosen cytokines and chemokines in blood sera and synovial fluid samples isolated from low disease activity rheumatoid arthritis (RA) patients and osteoarthritis (OA) sufferers. Blood sera and synovial fluid samples have been obtained from 24 OA and 14 RA patients. Cytokines/chemokines levels have been determined using a Milliplex® Map 38-plex human cytokine/chemokine magnetic bead-based panel (Merck Millipore, Germany) and Luminex® MAGPIX® platform (Luminex USA). Low disease activity RA patients showed altered concentration of numerous cytokine/chemokine when compared to OA controls—they were characterized by, inter alia, increased: eotaxin/CCL11 (p = 0.037), GRO/CXCL1 (p = 0.037), IL-2 (p = 0.013), IL-4 (p = 0.017), IL-7 (p = 0.003), IL-8 (p = 0.0007) and GM-CSF (p = 0.037) serum levels, whilst MDC/CCL22 concentration was decreased in this group (p = 0.034). Eotaxin/CCL11 (p = 0.001), GRO/CXCL1 (p = 0.041), IL-10 (p = 0.003), GM-CSF (p = 0.01), IL-1RA (p = 0.0005) and VEGF (p = 0.01) concentrations in synovial fluid of RA females were also increased. Even with low disease activity score, RA patients exhibited increased concentrations of cytokines with pro- and anti-inflammatory activities, as well as numerous chemokines, growth factors and regulators of angiogenesis. Surprisingly, RA subjects also shown decreased concentration of CCL22 chemokine. The attempt to restore cytokine balance and tolerogenic environment is ineffective in RA sufferers even with good disease management. Distinguished factors could serve as possible indicators of disease progression even in low disease activity patients.
Collapse
Affiliation(s)
- Maria Skrzypkowska
- Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Dębinki 1, 80-210 Gdańsk, Poland
| | - Mariusz Stasiak
- Second Clinic of Orthopaedics and Kinetic Organ Traumatology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Justyna Sakowska
- Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Dębinki 1, 80-210 Gdańsk, Poland
| | - Joanna Chmiel
- Second Clinic of Orthopaedics and Kinetic Organ Traumatology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - Agata Maciejewska
- Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Dębinki 1, 80-210 Gdańsk, Poland
| | - Adam Buciński
- Department of Biopharmacy, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
| | - Bartosz Słomiński
- Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Dębinki 1, 80-210 Gdańsk, Poland
| | - Piotr Trzonkowski
- Department of Medical Immunology, Faculty of Medicine, Medical University of Gdańsk, Dębinki 1, 80-210 Gdańsk, Poland
| | - Piotr Łuczkiewicz
- Second Clinic of Orthopaedics and Kinetic Organ Traumatology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
4
|
Ma M, Yang W, Cai Z, Wang P, Li H, Mi R, Jiang Y, Xie Z, Sui P, Wu Y, Shen H. SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis. STEM CELLS (DAYTON, OHIO) 2021; 39:581-599. [PMID: 33547700 PMCID: PMC8248389 DOI: 10.1002/stem.3332] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 11/18/2020] [Accepted: 12/10/2020] [Indexed: 12/13/2022]
Abstract
Dysregulated angiogenesis of mesenchymal stem cells (MSCs) is closely related to inflammation and disrupted bone metabolism in patients with various autoimmune diseases. However, the role of MSCs in the development of abnormal angiogenesis in patients with ankylosing spondylitis (AS) remains unclear. In this study, we cultured human umbilical vein endothelial cells (HUVECs) with bone marrow-derived MSCs from patients with AS (ASMSCs) or healthy donors (HDMSCs) in vitro. Then, the cocultured HUVECs were assayed using a cell counting kit-8 (CCK-8) to evaluate the cell proliferation. A wound healing assay was performed to investigate cell migration, and a tube formation assay was conducted to determine the angiogenesis efficiency. ASMSCs exhibited increased angiogenesis, and increased expression of SMAD-specific E3 ubiquitin ligase 2 (Smurf2) in MSCs was the main cause of abnormal angiogenesis in patients with AS. Downregulation of Smurf2 in ASMSCs blocked angiogenesis, whereas overexpression of Smurf2 in HDMSCs promoted angiogenesis. The pro-angiogenic effect of Smurf2 was confirmed by the results of a Matrigel plug assay in vivo. By functioning as an E3 ubiquitin ligase in MSCs, Smurf2 regulated the levels of pentraxin 3 (PTX3), which has been shown to suppress angiogenesis through the PTX3-fibroblast growth factor 2 pathway. Moreover, Smurf2 transcription was regulated by activating transcription factor 4-induced endoplasmic reticulum stress. In conclusion, these results identify novel roles of Smurf2 in negatively regulating PTX3 stability and promoting angiogenesis in ASMSCs.
Collapse
Affiliation(s)
- Mengjun Ma
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Wen Yang
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Zhaopeng Cai
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Peng Wang
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Hongyu Li
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Rujia Mi
- Center for Biotherapy, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Yuhang Jiang
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Zhongyu Xie
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Pengfei Sui
- State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, People's Republic of China
| | - Yanfeng Wu
- Center for Biotherapy, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China
| | - Huiyong Shen
- Department of Orthopedics, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China.,Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China
| |
Collapse
|
5
|
Cai Z, Wu B, Ye G, Liu W, Chen K, Wang P, Xie Z, Li J, Zheng G, Yu W, Su Z, Lin J, Wu Y, Shen H. Enhanced Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells in Ossification of the Posterior Longitudinal Ligament Through Activation of the BMP2-Smad1/5/8 Pathway. Stem Cells Dev 2020; 29:1567-1576. [PMID: 33096960 DOI: 10.1089/scd.2020.0117] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Ossification of the posterior longitudinal ligament (OPLL) is characterized by ectopic OPLL. To date, the specific molecular pathogenesis of OPLL has not been clearly elucidated. In this study, bone marrow-derived mesenchymal stem cells obtained from healthy donors (HD-MSCs) and patients with OPLL (OPLL-MSCs) were cultured in osteogenic differentiation medium for 21 days. The osteogenic differentiation capacity was determined by alizarin red S (ARS) and alkaline phosphatase (ALP) assays. Gene expression levels of osteoblastic markers were measured by quantitative reverse transcription-polymerase chain reaction. Protein levels of related genes and the activation of related signaling pathways were measured by western blotting. LDN193189 was used to inhibit the Smad1/5/8 pathway, and small interfering RNA was used to regulate BMP2 expression. Our results showed that the OPLL-MSCs had stronger ARS staining and ALP activity and higher expression of RUNX2, Osterix, and OCN than the HD-MSCs. During osteogenic differentiation, the Smad1/5/8 pathway was overactivated in the OPLL-MSCs, and LDN193189 inhibition reversed the enhanced osteogenic ability of these cells. Besides, BMP2 was upregulated in the OPLL-MSCs. After BMP2 knockdown, the abnormal osteogenic differentiation of OPLL-MSCs was rescued. Thus, abnormal activation of the BMP2-Smad1/5/8 pathway induces enhanced osteogenic differentiation of OPLL-MSCs compared with HD-MSCs. These findings reveal a mechanism of pathological osteogenesis in OPLL and provide a new perspective on inhibiting pathological osteogenesis by regulating BMP2.
Collapse
Affiliation(s)
- Zhaopeng Cai
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Boyang Wu
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Guiwen Ye
- Department of Orthopedics, and Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Wenjie Liu
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Keng Chen
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Peng Wang
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Zhongyu Xie
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Jinteng Li
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Guan Zheng
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Wenhui Yu
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Zepeng Su
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Jiajie Lin
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
| | - Yanfeng Wu
- Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Huiyong Shen
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.,Department of Orthopedics, and Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
6
|
Harrell CR, Markovic BS, Fellabaum C, Arsenijevic N, Djonov V, Volarevic V. The role of Interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration. Biofactors 2020; 46:263-275. [PMID: 31755595 DOI: 10.1002/biof.1587] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 09/27/2019] [Accepted: 10/19/2019] [Indexed: 12/13/2022]
Abstract
Interleukin (IL)-1 receptor antagonist (IL-1Ra), a naturally occurring antagonist of IL-1α/IL-1β signaling pathways, has been attributed to the immunosuppressive effects of mesenchymal stem cells (MSCs). MSCs, in IL-1Ra-dependent manner, suppressed production of IL-1β in dermal macrophages, induced their polarization in anti-inflammatory M2 phenotype, attenuated antigen-presenting properties of dendritic cells (DCs), and promoted expansion of immunosuppressive T regulatory cells in the skin, which resulted in enhanced repair of the nonhealing wounds. Reduced activation of inflammasome and suppressed production of IL-1β in macrophages were mainly responsible for beneficial effects of MSC-derived IL-1Ra in alleviation of acute lung injury, dry eye syndrome, and corneal injury. Through the production of IL-1Ra, MSCs reduced migration of DCs to the draining lymph nodes and attenuated generation of inflammatory Th1 and Th17 cells that resulted in alleviation of fulminant hepatitis and rheumatoid arthritis. MSCs, in IL-1Ra-dependent manner, reduced liver fibrosis by suppressing production of Type I collagen in hepatic stellate cells. IL-1Ra was, at least partially, responsible for enhanced proliferation of hepatocytes and chondrocytes in MSC-treated animals with partial hepatectomy and osteoarthritis. Despite of these beneficial effects, IL-1Ra-dependent inhibition of IL-1α/IL-1β-signaling significantly increased risk of infections. Therefore, future experimental and clinical studies should delineate potential side effects of MSC-derived IL-1Ra before IL-1Ra-overexpressing MSCs could be used as a potentially new therapeutic agent for the treatment of acute and chronic inflammatory diseases.
Collapse
Affiliation(s)
| | - Bojana Simovic Markovic
- Faculty of Medical Sciences, Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia
| | | | - Nebojsa Arsenijevic
- Faculty of Medical Sciences, Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia
| | | | - Vladislav Volarevic
- Faculty of Medical Sciences, Department for Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Kragujevac, Serbia
| |
Collapse
|
7
|
Enhanced osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis: a study based on a three-dimensional biomimetic environment. Cell Death Dis 2019; 10:350. [PMID: 31024000 PMCID: PMC6484086 DOI: 10.1038/s41419-019-1586-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 03/17/2019] [Accepted: 04/10/2019] [Indexed: 12/27/2022]
Abstract
The mechanism of pathological osteogenesis in Ankylosing spondylitis (AS) is largely unknown. Our previous studies demonstrated that the imbalance between BMP-2 and Noggin secretion induces abnormal osteogenic differentiation of marrow-derived mesenchymal stem cells (MSCs) from AS patients in a two-dimensional culture environment. In this study, HA/β-TCP scaffolds were further used as a three-dimensional (3D) biomimetic culture system to mimic the bone microenvironment in vivo to determine the abnormal osteogenic differentiation of AS-MSCs. We demonstrated that when cultured in HA/β-TCP scaffolds, AS-MSCs had a stronger osteogenic differentiation capacity than that of MSCs from healthy donors (HD-MSCs) in vitro and in vivo. This dysfunction resulted from BMP2 overexpression in AS-MSCs, which excessively activated the Smad1/5/8 and ERK signalling pathways and finally led to enhanced osteogenic differentiation. Both the signalling pathway inhibitors and siRNAs inhibiting BMP2 expression could rectify the enhanced osteogenic differentiation of AS-MSCs. Furthermore, BMP2 expression in ossifying entheses was significantly higher in AS patients. In summary, our study demonstrated that AS-MSCs possess enhanced osteogenic differentiation in HA/β-TCP scaffolds as a 3D biomimetic microenvironment because of BMP2 overexpression, but not Noggin. These results provide insights into the mechanism of pathological osteogenesis, which can aid in the development of niche-targeting medications for AS.
Collapse
|
8
|
Park EH, Lim HS, Lee S, Roh K, Seo KW, Kang KS, Shin K. Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial. Stem Cells Transl Med 2018; 7:636-642. [PMID: 30112846 PMCID: PMC6127229 DOI: 10.1002/sctm.18-0031] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 05/04/2018] [Accepted: 05/09/2018] [Indexed: 12/11/2022] Open
Abstract
Based on immunomodulatory actions of human umbilical cord blood‐derived mesenchymal stem cells (hUCB‐MSCs), in vitro or preclinical studies of hUCB‐MSCs have been conducted extensively in rheumatoid arthritis (RA). However, few human trials have investigated the outcomes of hUCB‐MSC infusions. The CURE‐iv trial was a phase I, uncontrolled, open label trial for RA patients with moderate disease activity despite treatment with methotrexate. The patients received a single intravenous infusion of 2.5 × 107, 5 × 107, or 1 × 108 cells of hUCB‐MSCs for 30 minutes, three patients in each cluster, with an increment of cell numbers when there was no dose‐limited adverse event. Clinical and safety assessments were performed during the study period, and serum cytokines were measured at baseline and 24 hours after the infusion. Out of 11 screened RA patients, 9 were enrolled. The participants were predominantly female (78%) and the mean age was 57.4 years. The mean disease duration was 9.5 years, and baseline 28‐joint disease activity score (DAS28; using erythrocyte sedimentation rate) was 4.53. There was no major toxicity in all clusters up to 4 weeks after the infusion. Serum erythrocyte sedimentation rate changes at 4 weeks (n = 9) were −7.9 ± 10.4 (p = .0517) and DAS28 changes were −1.60 ± 1.57 (p = .0159). Reduced levels of IL‐1β, IL‐6, IL‐8, and TNF‐α at 24 hours were observed in the cluster infused with 1 × 108 MSCs. This phase Ia hUCB‐MSC infusion trial for established RA patients revealed no short‐term safety concerns. Stem Cells Translational Medicine2018
Collapse
Affiliation(s)
- Eun Hye Park
- Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
| | - Hee-Suk Lim
- Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea
| | - Seunghee Lee
- Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea
| | - Kyounghwan Roh
- Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea
| | - Kwang-Won Seo
- Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea
| | - Kyung-Sun Kang
- Institute for Stem cell Regenerative Medicine, Kangstem Biotech, Seoul, South Korea.,Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, South Korea
| | - Kichul Shin
- Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea
| |
Collapse
|
9
|
Yamagata K, Nakayamada S, Tanaka Y. Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. Inflamm Regen 2018; 38:4. [PMID: 29560045 PMCID: PMC5846298 DOI: 10.1186/s41232-018-0061-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 02/26/2018] [Indexed: 01/25/2023] Open
Abstract
Articular cartilage has poor capacity for repair. Once damaged, they degenerate, causing functional impairment of joints. Allogeneic cartilage transplantation has been performed for functional recovery of articular cartilage. However, there is only a limited amount of articular cartilage available for transplantation. Mesenchymal stem cells (MSCs) could be potentially suitable for local implantation. MSCs can differentiate into chondrocytes. Several studies have demonstrated the therapeutic potential of MSCs in the repair of articular cartilage in animal models of articular cartilage damage and in patients with damaged articular cartilage. To boost post-implantation MSC differentiation into chondrocytes, the alternative delivery methods by scaffolds, using hyaluronic acid (HA) or poly-lactic-co-glycolic-acid (PLGA), have developed. In this review, we report recent data on the repair of articular cartilage and discuss future developments.
Collapse
Affiliation(s)
- Kaoru Yamagata
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555 Japan
| | - Shingo Nakayamada
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555 Japan
| | - Yoshiya Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, 807-8555 Japan
| |
Collapse
|
10
|
Xie Z, Tang S, Ye G, Wang P, Li J, Liu W, Li M, Wang S, Wu X, Cen S, Zheng G, Ma M, Wu Y, Shen H. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther 2018; 9:13. [PMID: 29357923 PMCID: PMC5776773 DOI: 10.1186/s13287-017-0766-0] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 12/24/2017] [Accepted: 12/27/2017] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Interleukin-6 (IL-6) with IL-6 receptor (IL-6R) play an important role in the tissue regeneration in vivo, especially bone metabolism. Bone marrow -derived mesenchymal stem cells (BM-MSCs) are multipotent stromal cells, which are main origin of osteoblasts. However, the roles of IL-6 and IL-6R in the osteogenic differentiation of BM-MSCs are still unclear. METHODS The expression of IL-6 and IL-6R was detected in BM-MSCs during osteogenic differentiation. The activation of the STAT3 pathway was assessed and its role in the osteogenic differentiation of BM-MSCs was determined using the specific inhibitor AG490. Exogenous IL-6/soluble IL-6R or antibodies against IL-6/IL-6R were used to confirm the mechanism by which the IL-6/IL-6R complex promotes the osteogenic differentiation. RESULTS The levels of IL-6 and IL-6R, especially the level of membranous IL-6R but not that of soluble IL-6R, increased during osteogenic differentiation in BM-MSCs. The levels of IL-6 and IL-6R were positively correlated with the osteogenic potential of BM-MSCs. The STAT3 signaling pathway was activated during the osteogenic differentiation of BM-MSCs. AG490 markedly inhibited the activation of the STAT3 pathway and, subsequently, the osteogenic differentiation potential of BM-MSCs. Additionally, exogenous IL-6 and soluble IL-6R accelerated the osteogenic differentiation of BM-MSCs. In contrast, antibodies against IL-6 or IL-6R suppressed the osteogenic differentiation of BM-MSCs. Moreover, IL-6 and IL-6R were found to stimulate each other's expression in BM-MSCs. CONCLUSIONS IL-6 and IL-6R levels increase during the osteogenic differentiation of BM-MSCs. These two molecules form a complex to activate the downstream STAT3 signaling pathway, which promotes osteogenic differentiation in BM-MSCs via an autocrine/paracrine feedback loop.
Collapse
Affiliation(s)
- Zhongyu Xie
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Su'an Tang
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Guiwen Ye
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Peng Wang
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Jinteng Li
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Wenjie Liu
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Ming Li
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Shan Wang
- Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Xiaohua Wu
- Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Shuizhong Cen
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Guan Zheng
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Mengjun Ma
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China
| | - Yanfeng Wu
- Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China.
| | - Huiyong Shen
- Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107# Yan Jiang Road West, Guangzhou, Guangdong, 510120, People's Republic of China.
| |
Collapse
|
11
|
Effect of integration time on the morphometric, densitometric and mechanical properties of the mouse tibia. J Biomech 2017; 65:203-211. [DOI: 10.1016/j.jbiomech.2017.10.026] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/22/2017] [Accepted: 10/27/2017] [Indexed: 12/14/2022]
|
12
|
Magrey MN, Khan MA. The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management. Curr Rheumatol Rep 2017; 19:17. [DOI: 10.1007/s11926-017-0644-x] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
13
|
Zhang JM, Feng FE, Wang QM, Zhu XL, Fu HX, Xu LP, Liu KY, Huang XJ, Zhang XH. Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. Stem Cells Transl Med 2016; 5:1631-1643. [PMID: 27471307 DOI: 10.5966/sctm.2015-0360] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2015] [Accepted: 05/13/2016] [Indexed: 12/12/2022] Open
Abstract
: Immune thrombocytopenia (ITP) is characterized by platelet destruction and megakaryocyte dysfunction. Mesenchymal stem cells (MSCs) from ITP patients (MSC-ITP) do not exhibit conventional proliferative abilities and thus exhibit defects in immunoregulation, suggesting that MSC impairment might be a mechanism involved in ITP. Platelet-derived growth factor (PDGF) improves growth and survival in various cell types. Moreover, PDGF promotes MSC proliferation. The aim of the present study was to analyze the effects of PDGF-BB on MSC-ITP. We showed that MSC-ITP expanded more slowly and appeared flattened and larger. MSC-ITP exhibited increased apoptosis and senescence compared with controls. Both the intrinsic and extrinsic pathways account for the enhanced apoptosis. P53 and p21 expression were upregulated in MSC-ITP, but inhibition of p53 with pifithrin-α markedly inhibited apoptosis and senescence. Furthermore, MSCs from ITP patients showed a lower capacity for inhibiting the proliferation of activated T cells inducing regulatory T cells (Tregs) and suppressing the synthesis of anti-glycoprotein (GP)IIb-IIIa antibodies. PDGF-BB treatment significantly decreased the expression of p53 and p21 and increased survivin expression in MSC-ITP. In addition, the apoptotic rate and number of senescent cells in ITP MSCs were reduced. Their impaired ability for inhibiting activated T cells, inducing Tregs, and suppressing the synthesis of anti-GPIIb-IIIa antibodies was restored after PDGF-BB treatment. In conclusion, we have demonstrated that PDGF-BB protects MSCs derived from ITP patients against apoptosis, senescence, and immunomodulatory defects. This protective effect of PDGF-BB is likely mediated via the p53/p21 pathway, thus potentially providing a new therapeutic approach for ITP. SIGNIFICANCE Immune thrombocytopenia (ITP) is characterized by platelet destruction and megakaryocyte dysfunction. Platelet-derived growth factor (PDGF) improves growth and survival in various cell types and promotes mesenchymal stem cell (MSC) proliferation. PDGF-BB protects MSCs derived from ITP patients against apoptosis, senescence, and immunomodulatory defects. This protective effect of PDGF-BB is likely mediated via the p53/p21 pathway, thus potentially providing a new therapeutic approach for ITP.
Collapse
Affiliation(s)
- Jia-Min Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China
- Collaborative Innovation Center of Hematology, Peking University, Beijing, People's Republic of China
| | - Fei-Er Feng
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
| | - Qian-Ming Wang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
| | - Xiao-Lu Zhu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
| | - Hai-Xia Fu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
| | - Lan-Ping Xu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China
- Collaborative Innovation Center of Hematology, Peking University, Beijing, People's Republic of China
| | - Kai-Yan Liu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China
- Collaborative Innovation Center of Hematology, Peking University, Beijing, People's Republic of China
| | - Xiao-Jun Huang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China
- Collaborative Innovation Center of Hematology, Peking University, Beijing, People's Republic of China
| | - Xiao-Hui Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China
- Collaborative Innovation Center of Hematology, Peking University, Beijing, People's Republic of China
| |
Collapse
|
14
|
Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H, Li D, Wu Y, Shen H. Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis. Arthritis Rheumatol 2016; 68:430-40. [PMID: 26413886 DOI: 10.1002/art.39433] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Accepted: 09/08/2015] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To study the osteogenic differentiation capacity of bone marrow-derived mesenchymal stem cells (BM-MSCs) from patients with ankylosing spondylitis (AS) and to investigate the mechanisms of abnormal osteogenic differentiation of BM-MSCs in AS. METHODS BM-MSCs from healthy donors (HD-MSCs) and patients with AS (AS-MSCs) were cultured in osteogenic differentiation medium for 0-21 days, after which their osteogenic differentiation capacity was determined using alizarin red S and alkaline phosphatase assays. Gene expression levels of osteoblastic markers and related cytokines were detected by high-throughput quantitative reverse transcription-polymerase chain reaction. Enzyme-linked immunosorbent assay was performed to detect protein levels of bone morphogenetic protein 2 (BMP-2) and Noggin in the cell culture supernatant. The activation of Smad1/5/8 and MAPK signaling pathways was measured by Western blotting. The balance between BMP-2 and Noggin expression was regulated using lentiviruses encoding short hairpin RNA and exogenous Noggin, respectively, which enabled evaluation of how this balance affected osteogenic differentiation of AS-MSCs. RESULTS AS-MSCs outperformed HD-MSCs in osteogenic differentiation capacity. During osteogenic differentiation, AS-MSCs secreted more BMP-2 but less Noggin, accompanied by an overactivation of Smad1/5/8 and ERK-1/2. When the Noggin concentration was increased or BMP-2 expression was inhibited, the abnormal osteogenic differentiation of AS-MSCs was rectified. In addition, the balance between BMP-2 and Noggin secretion was restored. CONCLUSION The results of this study demonstrate that an imbalance between BMP-2 and Noggin secretion induces abnormal osteogenic differentiation of AS-MSCs. These findings reveal a mechanism of pathologic osteogenesis in AS and provide a new perspective on inhibiting pathologic osteogenesis by regulating the balance between BMP-2 and Noggin.
Collapse
Affiliation(s)
- Zhongyu Xie
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Peng Wang
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Yuxi Li
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Wen Deng
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Xin Zhang
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Hongjun Su
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Deng Li
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Yanfeng Wu
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| | - Huiyong Shen
- Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
15
|
Xie Z, Li J, Wang P, Li Y, Wu X, Wang S, Su H, Deng W, Liu Z, Cen S, Ouyang Y, Wu Y, Shen H. Differential Expression Profiles of Long Noncoding RNA and mRNA of Osteogenically Differentiated Mesenchymal Stem Cells in Ankylosing Spondylitis. J Rheumatol 2016; 43:1523-31. [PMID: 27182066 DOI: 10.3899/jrheum.151181] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2016] [Indexed: 02/07/2023]
Abstract
OBJECTIVE We previously demonstrated that mesenchymal stem cells (MSC) from patients with ankylosing spondylitis (AS; ASMSC) have a greater osteogenic differentiation capacity than MSC from healthy donors (HDMSC) and that this difference underlies the pathogenesis of pathological osteogenesis in AS. Here we compared expression levels of long noncoding RNA (lncRNA) and mRNA between osteogenically differentiated ASMSC and HDMSC and explored the precise mechanism underlying abnormal osteogenic differentiation in ASMSC. METHODS HDMSC and ASMSC were induced with osteogenic differentiation medium for 10 days. Microarray analyses were then performed to identify lncRNA and mRNA differentially expressed between HDMSC and ASMSC, which were then subjected to bioinformatics analysis and confirmed by quantitative real-time PCR (qRT-PCR) assays. In addition, coding-non-coding gene co-expression (CNC) networks were constructed to examine the relationships between the lncRNA and mRNA expression patterns. RESULTS A total of 520 lncRNA and 665 mRNA were differentially expressed in osteogenically differentiated ASMSC compared with HDMSC. Bioinformatics analysis revealed 64 signaling pathways with significant differences, including transforming growth factor-β signaling. qRT-PCR assays confirmed the reliability of the microarray data. The CNC network indicated that 4 differentially expressed lncRNA, including lnc-ZNF354A-1, lnc-LIN54-1, lnc-FRG2C-3, and lnc-USP50-2 may be involved in the abnormal osteogenic differentiation of ASMSC. CONCLUSION Our study characterized the differential lncRNA and mRNA expression profiles of osteogenically differentiated ASMSC and identified 4 lncRNA that may participate in the abnormal osteogenic differentiation of ASMSC. These results provide insight into the pathogenesis of pathological osteogenesis in AS.
Collapse
Affiliation(s)
- Zhongyu Xie
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Jinteng Li
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Peng Wang
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Yuxi Li
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Xiaohua Wu
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Shan Wang
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Hongjun Su
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Wen Deng
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Zhenhua Liu
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Shuizhong Cen
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Yi Ouyang
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Yanfeng Wu
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
| | - Huiyong Shen
- From the Department of Orthopedics, and the Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China.Z. Xie, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; J. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; P. Wang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Li, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; X. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Wang, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Su, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; W. Deng, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Z. Liu, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; S. Cen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Ouyang, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Y. Wu, MD, Center for Biotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; H. Shen, MD, Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University.
| |
Collapse
|
16
|
Loukov D, Naidoo A, Puchta A, Marin JLA, Bowdish DME. Tumor necrosis factor drives increased splenic monopoiesis in old mice. J Leukoc Biol 2016; 100:121-9. [DOI: 10.1189/jlb.3ma0915-433rr] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Accepted: 03/12/2016] [Indexed: 12/24/2022] Open
|
17
|
Chiang ER, Ma HL, Wang JP, Liu CL, Chen TH, Hung SC. Multi-lineage differentiation and angiogenesis potentials of pigmented villonodular synovitis derived mesenchymal stem cells--pathological implication. J Orthop Res 2016; 34:395-403. [PMID: 26291329 DOI: 10.1002/jor.23031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 08/11/2015] [Indexed: 02/04/2023]
Abstract
Pigmented villonodular synovitis (PVNS) is a benign tissue proliferation characterized by its hyper-vascularity within the lesion. The true etiology and cell source of this disease entity still remain unclear. Mesenchymal stem cells (MSCs) exist in various tissues of human body. However, it has not been clarified whether MSCs could be isolated from tissue of PVNS. Here, we isolated MSCs from PVNS (PVNS-SCs), and by comparing to the MSCs from normal synovium (Syn-SCs) of the same individual, we investigated whether PVNS-SCs differed in the capacity for multi-differentiation and inducing angiogenesis. We first demonstrated that PVNS-SCs existed in the lesion of PVNS of three individuals. Moreover, we showed PVNS-SCs had better osteogenic differentiation potential than Syn-SCs, whereas Syn-SCs had better capacity for adipogenic and chondrogenic differentiation. By genome-wide analysis of gene expression profile using a complementary DNA microarray and comparing to Syn-SCs, we identified in PVNS-SCs a distinct gene expression profile characterized by up-regulation of genes involved in angiogenesis. In vitro and in vivo studies further confirmed that PVNS-SCs had better capacities for promoting angiogenesis. In summary, the identification of PVNS-SCs in PVNS tissue and their distinct angiogenic potential may help elucidate the underlying etiology of this disease.
Collapse
Affiliation(s)
- En-Rung Chiang
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Hsiao-Li Ma
- Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Jung-Pan Wang
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chien-Lin Liu
- Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Tain-Hsiung Chen
- Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Shih-Chieh Hung
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan.,Department of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.,Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.,Integrative Stem Cell Center, China Medical University, Taichung, Taiwan
| |
Collapse
|
18
|
Gomes AC, Gomes MS. Hematopoietic niches, erythropoiesis and anemia of chronic infection. Exp Hematol 2015; 44:85-91. [PMID: 26615156 DOI: 10.1016/j.exphem.2015.11.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 11/06/2015] [Accepted: 11/09/2015] [Indexed: 02/07/2023]
Abstract
Anemia is a significant co-morbidity of chronic infections, as well as other inflammatory diseases. Anemia of chronic infection results from defective bone marrow erythropoiesis. Although the limitation of iron availability has been considered a key factor, the exact mechanisms underlying blockade in erythroid generation during infection are not fully understood. Erythropoiesis is a tightly regulated process that is very sensitive to environmental changes. During the last decade, the importance of the bone marrow hematopoietic niche has been progressively acknowledged. Several bone marrow cell types (such as macrophages, mesenchymal stem cells, and progenitor cells) and molecular mediators (such as CXCL12) have been identified as fundamental for both the maintenance of hematopoietic stem cell pluripotency and their most adequate differentiation into each hematopoietic cell lineage. Importantly, both niche-supporting cells and hematopoietic progenitors were found to be able to sense local and systemic cues to adapt the hematopoietic output to needs of the organism. Here, we review how hematopoietic progenitors and niche-supporting cells sense and respond to stress cues and suggest a potential role for the hematopoietic niche in the development of anemia of chronic infection.
Collapse
Affiliation(s)
- Ana Cordeiro Gomes
- Graduate Program in Biomedical Sciences, ICBAS-Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal
| | - Maria Salomé Gomes
- Department of Molecular Biology, ICBAS-Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal; IBMC-Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.
| |
Collapse
|
19
|
Reitinger S, Schimke M, Klepsch S, de Sneeuw S, Yani SL, Gaßner R, Ertl P, Lepperdinger G. Systemic impact molds mesenchymal stromal/stem cell aging. Transfus Apher Sci 2015; 52:285-9. [PMID: 25910539 DOI: 10.1016/j.transci.2015.04.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Aging is associated with an accruing emergence of non-functional tissues. Mesenchymal stem cells (MSC) bring forth progenitors with multi-lineage differentiation potential, yet, they also exhibit anti-inflammatory and tissue-protective properties. Due to aging, altered tissue microenvironments constrict controlled stem cell proliferation and progenitor differentiation, thus diminishing the fitness of MSC. Therefore, deepening our understanding of metabolic, molecular and environmental factors impacting on MSC during human aging as well as providing new vistas on their role in promoting healthy aging and preventing age-associated disease is pivot. It is anticipated that integrative quantification of systemic parameters dominantly impacting on MSC will also enable effective personalized prognosis and provision of effective early medical interventions. Working along this line, it can be envisaged that standards in medical therapies can be individually adjusted by accounting not solely for the patient's chronological age or other physical parameters rather than specific physiological parameters which are believed to functionally shape stem cell niches within the bone marrow.
Collapse
Affiliation(s)
- Stephan Reitinger
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria
| | - Magdalena Schimke
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria
| | - Sebastian Klepsch
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria
| | - Snezana de Sneeuw
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria
| | - Stella Lukas Yani
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria
| | - Robert Gaßner
- University Clinic for Maxillofacial Surgery Innsbruck, Anichstr. 35, Innsbruck A-6020, Austria
| | - Peter Ertl
- Austrian Institute for Technology, Muthgasse 11, Wien A-1190, Austria
| | - Günter Lepperdinger
- Institute for Biomedical Aging Research, University Innsbruck, Rennweg 10, Innsbruck A-6020, Austria; Department of Cell Biology and Genetics, University Salzburg, Hellbrunnerstr. 34, Salzburg 5020, Austria.
| |
Collapse
|
20
|
Mesenchymal stem cells from patients with rheumatoid arthritis display impaired function in inhibiting Th17 cells. J Immunol Res 2015; 2015:284215. [PMID: 25918734 PMCID: PMC4397051 DOI: 10.1155/2015/284215] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Revised: 03/03/2015] [Accepted: 03/04/2015] [Indexed: 12/18/2022] Open
Abstract
Mesenchymal stem cells (MSCs) possess multipotent and immunomodulatory properties and are suggested to be involved in the pathogenesis of immune-related diseases. This study explored the function of bone marrow MSCs from rheumatoid arthritis (RA) patients, focusing on immunomodulatory effects. RA MSCs showed decreased proliferative activity and aberrant migration capacity. No significant differences were observed in cytokine profiles between RA and control MSCs. The effects of RA MSCs on proliferation of peripheral blood mononuclear cells (PBMCs) and distribution of specific CD4(+) T cell subtypes (Th17, Treg, and Tfh cells) were investigated. RA MSCs appeared to be indistinguishable from controls in suppressing PBMC proliferation, decreasing the proportion of Tfh cells, and inducing the polarization of Treg cells. However, the capacity to inhibit Th17 cell polarization was impaired in RA MSCs, which was related to the low expression of CCL2 in RA MSCs after coculture with CD4(+) T cells. These findings indicated that RA MSCs display defects in several important biological activities, especially the capacity to inhibit Th17 cell polarization. These functionally impaired MSCs may contribute to the development of RA disease.
Collapse
|
21
|
Remission of collagen-induced arthritis through combination therapy of microfracture and transplantation of thermogel-encapsulated bone marrow mesenchymal stem cells. PLoS One 2015; 10:e0120596. [PMID: 25774788 PMCID: PMC4361318 DOI: 10.1371/journal.pone.0120596] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 01/24/2015] [Indexed: 12/11/2022] Open
Abstract
The persistent inflammation of rheumatoid arthritis (RA) always leads to partial synovial hyperplasia and the destruction of articular cartilage. Bone marrow mesenchymal stem cells (BMMSCs) have been proven to possess immunosuppressive effects, and widely explored in the treatment of autoimmune diseases. However, poor inhibitory effect on local inflammatory state and limited capacity of preventing destruction of articular cartilage by systemic BMMSCs transplantation were observed. Herein, toward the classical type II collagen-induced arthritis in rats, the combination treatment of microfracture and in situ transplantation of thermogel-encapsulated BMMSCs was verified to obviously down-regulate the ratio of CD4+ to CD8+ T lymphocytes in peripheral blood. In addition, it resulted in the decreased levels of inflammatory cytokines, such as interleukin-1β, tumor necrosis factor-α and anti-collagen type II antibody, in the serum. Simultaneously, the combination therapy also could inhibit the proliferation of antigen specific lymphocytes and local joint inflammatory condition, and prevent the articular cartilage damage. The results indicated that the treatment programs could effectively stimulate the endogenous and exogenous BMMSCs to exhibit the immunosuppression and cartilage protection capability. This study provided a new therapeutic strategy for autoimmune inflammatory diseases, such as RA.
Collapse
|
22
|
Matsukura Y, Muneta T, Tsuji K, Miyatake K, Yamada J, Abula K, Koga H, Tomita M, Sekiya I. Mouse synovial mesenchymal stem cells increase in yield with knee inflammation. J Orthop Res 2015; 33:246-53. [PMID: 25403845 PMCID: PMC4359008 DOI: 10.1002/jor.22753] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Accepted: 09/19/2014] [Indexed: 02/04/2023]
Abstract
Even though mouse studies have various advantages, harvesting an adequate number of synovial mesenchymal stem cells (MSCs) is difficult in mice. We investigated whether the total yield of MSCs increased in synovium with inflammation in mice. Infrapatellar fat pads (IFPs) were harvested from 10 knees of 5 mice 3, 7, and 14 days after intraarticular injection of carrageenan. Ten IFPs were also harvested from untreated knees as a control. Seven days after initial plating, the total yield of cells was compared among the 4 groups (n = 4-6). The harvested cells were analyzed for multipotentiality and surface epitopes. Furthermore, knee synovitis was compared among the 4 groups in histology. The number of cells in the 3 and 7 days treated group was significantly higher than the other groups. The harvested cells had characteristics of MSCs. Synovitis in the 3 and 7 days treated groups was significantly severer than the other groups. There seemed to be a relationship between the synovitis score and the total yield of cells derived from IFPs. In mice, it became possible to increase the yield 50-fold by inducing inflammation. This method makes it possible to analyze the molecular mechanisms of cartilage regeneration of synovial MSCs in mice models.
Collapse
Affiliation(s)
- Yu Matsukura
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Takeshi Muneta
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Kunikazu Tsuji
- Department of Cartilage Regeneration, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Kazumasa Miyatake
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Jun Yamada
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Kahaer Abula
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Hideyuki Koga
- Department of Joint Surgery and Sports Medicine, Graduate School, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Makoto Tomita
- Clinical Research Center, Tokyo Medical and Dental UniversityTokyo, Japan
| | - Ichiro Sekiya
- Center for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental UniversityTokyo, Japan,Correspondence to: Ichiro Sekiya (T: +81-3-5803-4017; F: +81-3-5803-0170; E-mail: )
| |
Collapse
|
23
|
Application of metabolomics in autoimmune diseases: Insight into biomarkers and pathology. J Neuroimmunol 2015; 279:25-32. [DOI: 10.1016/j.jneuroim.2015.01.001] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Revised: 10/09/2014] [Accepted: 01/05/2015] [Indexed: 12/31/2022]
|
24
|
Zhang D, Li H, Ma L, Zhang X, Xue F, Zhou Z, Chi Y, Liu X, Huang Y, Yang Y, Yang R. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 2014; 47:519-29. [DOI: 10.3109/08916934.2014.938320] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Donglei Zhang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Huiyuan Li
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Li Ma
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Xian Zhang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Feng Xue
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Zeping Zhou
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
- Department of Hematology, The Second Affiliated Hospital of Kunming Medical University
KunmingChina
| | - Ying Chi
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Xiaofan Liu
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Yueting Huang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| | - Yanhui Yang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
- Key Laboratory of Hormones and Development (Ministry of Health), 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics
TianjinChina
| | - Renchi Yang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College TianjinChina
| |
Collapse
|
25
|
Wang L, Wang L, Cong X, Liu G, Zhou J, Bai B, Li Y, Bai W, Li M, Ji H, Zhu D, Wu M, Liu Y. Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Active Rheumatoid Arthritis: Safety and Efficacy. Stem Cells Dev 2013; 22:3192-202. [PMID: 23941289 DOI: 10.1089/scd.2013.0023] [Citation(s) in RCA: 172] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Affiliation(s)
- Liming Wang
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Lihua Wang
- The State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Graduate School of Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China
| | - Xiuli Cong
- Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co. Ltd, Tianjin, China
| | - Guangyang Liu
- Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co. Ltd, Tianjin, China
| | - Jianjun Zhou
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Bin Bai
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Yang Li
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Wen Bai
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Ming Li
- Cell Therapy Center, 323 Hospital of Chinese People's Liberation Army, Xi'an city, China
| | - Haijie Ji
- Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co. Ltd, Tianjin, China
| | - Delin Zhu
- Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co. Ltd, Tianjin, China
| | - Mingyuan Wu
- Harold Hamm Diabetes Center and Section of Endocrinology and Diabetes in the Department of Internal Medicine, and Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
- School of Life Sciences and Technology, Tongji University, Shanghai, China
| | - Yongjun Liu
- Alliancells Institute of Stem Cells and Translational Regenerative Medicine of Zhongyuan Union Stem Cell Bioengineering Co. Ltd, Tianjin, China
- School of Life Sciences and Technology, Tongji University, Shanghai, China
| |
Collapse
|
26
|
Ragni E, Montemurro T, Montelatici E, Lavazza C, Viganò M, Rebulla P, Giordano R, Lazzari L. Differential microRNA signature of human mesenchymal stem cells from different sources reveals an “environmental-niche memory” for bone marrow stem cells. Exp Cell Res 2013; 319:1562-74. [DOI: 10.1016/j.yexcr.2013.04.002] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Revised: 03/14/2013] [Accepted: 04/01/2013] [Indexed: 01/20/2023]
|
27
|
MacFarlane RJ, Graham SM, Davies PSE, Korres N, Tsouchnica H, Heliotis M, Mantalaris A, Tsiridis E. Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets 2013; 17:243-54. [PMID: 23293906 DOI: 10.1517/14728222.2013.746954] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Mesenchymal stem cells (MSCs) are multipotent stromal cells characterized by their ability to differentiate into adipocytes, chondrocytes, osteocytes and a number of other lineages. Investigation into their use has increased in recent years as characterization of their immunomodulatory properties has developed, and their role in the pathophysiology of joint disease has been suggested. AREAS COVERED MSCs demonstrate immunosuppressive functionality by suppressing T- and B-cell responses following activation by cytokines such as IL-6 and IL-1α. They also can be induced to exert pro-inflammatory effects in the presence of acute inflammatory environment due to the actions of TNF-α and IFN-γ. In inflammatory joint diseases such as rheumatoid arthritis, MSCs in bone marrow migrate to joints by a TNF-α-dependent mechanism and may be in part responsible for the disease process. MSCs have also been demonstrated in increased numbers in periarticular tissues in osteoarthritis, which may reflect an attempt at joint regeneration. EXPERT OPINION Clinical applications for MSCs have shown promise in a number of inflammatory and autoimmune disorders. Future work is likely to further reveal the immunosuppressive characteristics of MSCs, their role in the pathophysiology of joint diseases and provide the basis for new avenues for treatment.
Collapse
Affiliation(s)
- Robert J MacFarlane
- The Royal Liverpool University Hospital, Department of Trauma and Orthopaedics, Prescot Street, Liverpool, Merseyside L7 8XP, UK
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Oshita K, Yamaoka K, Kondo M, Tanaka Y. Regulatory role of mesenchymal stem cells in osteoclast differentiation. Inflamm Regen 2013. [DOI: 10.2492/inflammregen.33.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
29
|
Lepperdinger G. Developmental programs are kept alive during adulthood by stem cells: the aging aspect. Exp Gerontol 2012; 48:644-6. [PMID: 22819756 DOI: 10.1016/j.exger.2012.07.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2011] [Revised: 07/03/2012] [Accepted: 07/05/2012] [Indexed: 01/14/2023]
Abstract
Stem cells are fundamental for life-long preservation of cellular somatic maintenance. Tissue-borne stem cells replenish worn-out critical elements. Provided they remain fit over lifetime, enduring stem cell activities avert the emergence of age-associated chronic degenerative diseases and pathologies. Although experimentally still unclear, it is assumed that stem cells reside in protected niches. Freshly isolated mesenchymal stem cells exhibit donor-specific aberrations, which cannot solely be ascribed to differences in genetic background. Besides inevitably accumulating intrinsic modifications, the systemic environment also impacts on basic properties of mesenchymal stem cells such as their inherent multi-lineage differentiation potential. Chronic systemic aberrations over time comprise unwholesome influences, in particular in terms of regeneration and repair when stem cells recapitulate distinct developmental programs. During or thereafter, stem cells can diversify either because of insufficiently silencing activated building cycles, or by acquiring epigenetic deviations.
Collapse
Affiliation(s)
- Günter Lepperdinger
- Austrian Academy of Sciences, Institute for Biomedical Aging Research, Rennweg 10, 6020 Innsbruck, Austria.
| |
Collapse
|
30
|
Raggi C, Berardi AC. Mesenchymal stem cells, aging and regenerative medicine. Muscles Ligaments Tendons J 2012; 2:239-242. [PMID: 23738303 PMCID: PMC3666525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Tissue maintenance and regeneration is dependent on stem cells and increasing evidence has shown to decline with age. Stem cell based-aging is thought to influence therapeutic efficacy. Mesenchymal stromal cells (MSCs) are involved in tissue regeneration. Here, we discuss the effects of age-related changes on MSC properties considering their possible use in research or regenerative medicine.
Collapse
Affiliation(s)
- Chiara Raggi
- Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - Anna C. Berardi
- Department of Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, Pescara, Italy
| |
Collapse
|
31
|
Brown HK, Ottewell PD, Evans CA, Coleman RE, Holen I. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. J Bone Oncol 2012; 1:47-56. [PMID: 26909255 PMCID: PMC4723328 DOI: 10.1016/j.jbo.2012.05.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2012] [Revised: 05/16/2012] [Accepted: 05/22/2012] [Indexed: 12/11/2022] Open
Abstract
We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3–4 weeks, the aim of the current study was to establish the anti-tumour and bone effects of a single administration of doxorubicin/zoledronic acid combination therapy in a bone metastasis model. MDA-MB-231-GFP cells were injected i.c. in 6-week-old nude mice. On day 2, animals received PBS, doxorubicin (2 mg/kg i.v.), zoledronic acid (100 μg/kg s.c.) or doxorubicin followed 24 h later by zoledronic acid. Anti-tumour effects were assessed on days 15/23 by quantification of apoptotic and proliferating cells and changes in expression of genes implicated in apoptosis, proliferation and bone turnover. Bone effects were assessed by μCT analysis, bone histomorphometry and measurement of serum markers. A tumour-free control group was included. Combination treatment reduced bone tumour burden compared to single agent or PBS control and increased levels of tumour cell apoptosis on day 15, but this was no longer detectable on day 23. Animals receiving zoledronic acid had increased bone density, without evidence of tumour-induced lesions. Bone histomorphometry showed that zoledronic acid caused a decrease in osteoblast and osteoclast numbers and an increase in osteoclast size, in both tumour-free and tumour-bearing animals. Our data show that although zoledronic acid modifies the bone microenvironment through effects on both osteoblasts and osteoclasts, this does not result in a significant anti-tumour effect in the absence of doxorubicin.
Collapse
Affiliation(s)
- H K Brown
- Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, UK
| | - P D Ottewell
- Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, UK
| | - C A Evans
- Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, UK
| | - R E Coleman
- Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, UK
| | - I Holen
- Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, UK
| |
Collapse
|
32
|
Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012; 2012:975871. [PMID: 22666272 PMCID: PMC3361338 DOI: 10.1155/2012/975871] [Citation(s) in RCA: 193] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Accepted: 02/29/2012] [Indexed: 12/13/2022] Open
Abstract
Given the observed efficacy of culture-expanded multipotential stromal cells, also termed mesenchymal stem cells (MSCs), in the treatment of graft-versus host and cardiac disease, it remains surprising that purity and potency characterization of manufactured cell batches remains rather basic. In this paper, we will initially discuss surface and molecular markers that were proposed to serve as the indicators of the MSC potency, in terms of their proliferative potential or the ability to differentiate into desired lineages. The second part of this paper will be dedicated to a critical discussion of surface markers of uncultured (i.e., native) bone marrow (BM) MSCs. Although no formal consensus has yet been reached on which markers may be best suited for prospective BM MSC isolation, markers that cross-react with MSCs of animal models (such as CD271 and W8-B2/MSCA-1) may have the strongest translational value. Whereas small animal models are needed to discover the in vivo function on these markers, large animal models are required for safety and efficacy testing of isolated MSCs, particularly in the field of bone and cartilage tissue engineering.
Collapse
|
33
|
Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis 2012; 29:927-38. [PMID: 22562502 DOI: 10.1007/s10585-012-9481-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2011] [Accepted: 04/11/2012] [Indexed: 12/31/2022]
Abstract
Bone metastasis is a common incurable complication of breast cancer affecting around 70% of patients with advanced disease. In order to improve outcomes for these patients, the cellular and molecular mechanisms underlying bone metastasis need to be established. The majority of studies to date have focused on end-stage disease and little is known about the events taking place following initial tumour cell colonisation of bone. Here we report the results of a longitudinal study that provides detailed analysis of the spatial and temporal relationship between bone and cancer cells during progression of bone metastasis. Tumour growth in bone was initiated by intra-cardiac inoculation of MDA-MB-231-GFP breast cancer cells in immunocompromised mice. Differentiating between areas of bone in direct contact with the tumour and areas distal to the cancer cells but within the tumour bearing bone, we performed comprehensive analyses of the number and distribution of osteoclasts and osteoblasts. Tumour colonies were detectable in bone from day 10, while reduced trabecular bone volume was apparent from day 19 onwards. Cancer-induced changes in osteoblast and osteoclast numbers differed substantially depending on whether or not the cells were in direct contact with the tumour. Compared to naïve controls, areas of bone in direct contact with the tumour had significantly reduced osteoblast but increased osteoclast numbers, whereas the reverse was found in distal areas. Our data demonstrate that tumour cells induce substantial changes in the bone microenvironment prior to the appearance of bone lesions, suggesting that early therapeutic intervention may be required to oppose the tumour-induced changes to the microenvironment und thus tumour progression.
Collapse
|
34
|
Okada A, Yamasaki S, Kawakami A. Functional change of synoviocytes and mesenchymal stromal cells through adipogenesis: A possible model of pannus and bone edema formation in rheumatoid arthritis. Inflamm Regen 2012. [DOI: 10.2492/inflammregen.32.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
35
|
Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. BONE MARROW RESEARCH 2011; 2011:353878. [PMID: 22046560 PMCID: PMC3196250 DOI: 10.1155/2011/353878] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/31/2011] [Revised: 07/26/2011] [Accepted: 07/26/2011] [Indexed: 12/24/2022]
Abstract
Hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are both adult stem cells residing in the bone marrow. MSCs interact with HSCs, they stimulate and enhance the proliferation of HSCs by secreting regulatory molecules and cytokines, providing a specialized microenvironment for controlling the process of hematopoiesis. In this paper we discuss how MSCs contribute to HSC niche, maintain the stemness and proliferation of HSCs, and support HSC transplantation.
Collapse
|
36
|
Lepperdinger G. Inflammation and mesenchymal stem cell aging. Curr Opin Immunol 2011; 23:518-24. [PMID: 21703839 PMCID: PMC3167021 DOI: 10.1016/j.coi.2011.05.007] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2011] [Revised: 05/23/2011] [Accepted: 05/25/2011] [Indexed: 02/06/2023]
Abstract
In adults, mesenchymal stromal cells contain tissue-specific multipotent stem cells, MSC, which can be found throughout the body. With advancing age, tight controls of regulatory networks, which guide MSC biology, gradually deteriorate. Aberrations within the MSC microenvironment such as chronic inflammation eventually lead to adverse manifestations, such as the accumulation of fat deposits in bone and muscles, impaired healing and fibrosis after severe injury, or altered hematopoiesis and autoimmunity. MSC can also specifically interact with a large variety of immune cells, and in doing so, they secrete cytoprotective and immunoregulatory molecules, which together with intercellular contacts mediate immune modulatory processes. This review comprehends the current knowledge regarding molecular mechanisms and cellular interactions that occur in stem cell niches, which are jointly shared between MSC and hematopoietic stem and progenitor cells, as well as those intracellular interdependences taking place between mesenchymal and a wide variety of hematopoietic progeny in particular T lymphocytes, which eventually perturb tissue homeostasis and immunology at advanced age.
Collapse
Affiliation(s)
- Günter Lepperdinger
- Institute for Biomedical Aging Research, Austrian Academy of Sciences, Rennweg 10, A-6020 Innsbruck, Austria.
| |
Collapse
|
37
|
Abstract
The last several decades have revealed numerous interactions between cells of the hematopoietic lineage and osteoblasts (OBs) of the mesenchymal lineage. For example, OBs are important players in the hematopoietic stem cell (HSC) niche and OBs are known to impact osteoclast (OC) development. Thus, although much is known regarding the impact OBs have on hematopoietic cells, less is known about the impact of hematopoietic cells on OBs. Here we will review this reciprocal relationship: the effects of hematopoietic cells on OBs. Specifically, we will examine the impact of hematopoietic cells such as HSCs, lymphocytes, and megakaryocytes, as well as the hematopoietic cell-derived OCs on OB proliferation, differentiation, and function.
Collapse
Affiliation(s)
- Monique Bethel
- Department of Orthopaedic Surgery, Indiana University School of Medicine, 1120 South Drive, FH 115, Indianapolis, IN 46202, USA
| | - Edward F. Srour
- Departments of Medicine, Pediatrics, and Microbiology and Immunology, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, 980 West Walnut Street, R3-C312, Indianapolis, IN 46202, USA
| | - Melissa A. Kacena
- Department of Orthopaedic Surgery, Indiana University School of Medicine, 1120 South Drive, FH 115, Indianapolis, IN 46202, USA
| |
Collapse
|
38
|
Savopoulos C, Dokos C, Kaiafa G, Hatzitolios A. Adipogenesis and osteoblastogenesis: trans-differentiation in the pathophysiology of bone disorders. Hippokratia 2011; 15:18-21. [PMID: 21607030 PMCID: PMC3093139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Mesechymal stem cells as pluripotent cells are involved in the differentiation of adipocytes under regulation of genes and transcription factors. The plasticity observed between adipocytes and osteoblasts differentiation is the basis of transdifferentiation, observed in both experimental and clinical level. This review analyzes not only the adipose tissue as an endocrine organ but also the underlying mechanism of trans-differentiation between adipocytes and osteoblasts. Fat and bone tissue interaction is altered by activation or silencing of genes, signaling molecules and transcription factors. Disorders of this interaction include ectopic ossification syndromes and other bone disorders like osteoporosis and multiple myeloma. Further research will reveal the instinct mechanisms of this imbalance in the pathophysiology of many metabolic disorders such as diabetes mellitus, atherogenesis e.t.c.
Collapse
Affiliation(s)
- Ch Savopoulos
- 1 Medical Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
| | | | | | | |
Collapse
|
39
|
Chung DJ, Hayashi K, Toupadakis CA, Wong A, Yellowley CE. Osteogenic proliferation and differentiation of canine bone marrow and adipose tissue derived mesenchymal stromal cells and the influence of hypoxia. Res Vet Sci 2010; 92:66-75. [PMID: 21075407 DOI: 10.1016/j.rvsc.2010.10.012] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Revised: 09/04/2010] [Accepted: 10/05/2010] [Indexed: 12/13/2022]
Abstract
The aim of this study was to compare the osteogenic and proliferative potential of canine mesenchymal stromal cells (cMSCs) derived from bone marrow (BM-cMSCs) and adipose tissue (AT-cMSCs). Proliferation potential was determined under varying oxygen tensions (1%, 5%, and 21% O(2)). Effects of reduced oxygen levels on the osteogenic differentiation of AT-cMSCs were also investigated. AT-cMSCs proliferated at a significantly faster rate than BM-cMSCs, although both cell types showed robust osteogenic differentiation. Culture in 5% and 1% O(2) impaired proliferation in cMSC from both sources and osteogenic differentiation in AT-cMSCs. Our data suggests that AT-cMSCs might be more suitable for use in a clinical situation, where large cell numbers are required for bone repair, due to their rapid proliferation combined with robust osteogenic potential. Our data also suggests that the inhibitory effects of hypoxia on both cell proliferation and differentiation should be considered when using MSCs in a potentially hypoxic environment such as a fracture site.
Collapse
Affiliation(s)
- Dai-Jung Chung
- Department of Surgical and Radiological Sciences, University of California Davis, Davis, CA 95616, USA
| | | | | | | | | |
Collapse
|
40
|
Jorgensen C. Mesenchymal stem cells in arthritis: role of bone marrow microenvironment. Arthritis Res Ther 2010; 12:135. [PMID: 20804569 PMCID: PMC2945053 DOI: 10.1186/ar3105] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Based on their capacity to suppress immune responses, multipotent mesenchymal stromal cells (MSCs) are intensively studied for regenerative medicine. Moreover, MSCs are potent immunomodulatory cells that occur through the secretion of soluble mediators including nitric oxide, transforming growth factor beta, and HLAG5. The MSCs, however, are also able to express inflammatory mediators such as prostaglandin E2 or IL-6. MSCs in the bone marrow are in close contact with T cells and B cells, and they regulate immunological memory by organizing defined numbers of dedicated survival niches for plasma cells and memory T cells in the bone marrow. The role of MSCs in arthritis remains controversial - in some studies, murine allogeneic MSCs are able to decrease arthritis; in other studies, MSCs worsen the local inflammation. A recent paper in Arthritis Research and Therapy shows that bone marrow MSCs have decreased osteoblastic potential in rheumatoid arthritis, which may be related to chronic inflammation or to loss of expression of IL-1 receptor agonist. That article raises the importance of the bone marrow microenvironment for MSC biology.
Collapse
|